Clinical pharmacological approach for balancing the use of daptomycin and linezolid in comparison with that of vancomycin in the treatment of MRSA-related infections

References

• Gasch O, Camoez M, Dominguez MA, et al. Predictive factors for early mortality among patients with methicillin-resistant Staphylococcus aureus bacteraemia. J Antimicrob Chemother 2013;68:1423-30
   PubMed Web of Science ®Google Scholar
• Hanberger H, Walther S, Leone M, et al. Increased mortality associated with methicillin-resistant Staphylococcus aureus (MRSA) infection in the intensive care unit: results from the EPIC II study. Int J Antimicrob Agents 2011;38:331-5
   PubMed Web of Science ®Google Scholar
• Holmes NE, Turnidge JD, Munckhof WJ, et al. Vancomycin minimum inhibitory concentration, host comorbidities and mortality in Staphylococcus aureus bacteraemia. Clin Microbiol Infect 2013;19:1163-8
   PubMed Web of Science ®Google Scholar
• Soriano A, Marco F, Martinez JA, et al. Influence of vancomycin minimum inhibitory concentration on the treatment of methicillin-resistant Staphylococcus aureus bacteremia. Clin Infect Dis 2008;46:193-200
   PubMed Web of Science ®Google Scholar
• Machado DP, Goldani LZ, Paiva RM, et al. The impact of serum vancomycin levels and minimum inhibitory concentrations of methicillin-resistant Staphylococcus aureus on mortality in patients with nosocomial pneumonia. Can J Infect Dis Med Microbiol 2013;24:e75-9
   PubMedGoogle Scholar
• Woods CJ, Chowdhury A, Patel VM, Shorr AF. Impact of vancomycin minimum inhibitory concentration on mortality among critically ill patients with methicillin-resistant Staphylococcus aureus bacteremia. Infect Control Hosp Epidemiol 2012;33:1246-9
   PubMedGoogle Scholar
• van Hal SJ, Lodise TP, Paterson DL. The clinical significance of vancomycin minimum inhibitory concentration in Staphylococcus aureus infections: a systematic review and meta-analysis. Clin Infect Dis 2012;54:755-71
   PubMed Web of Science ®Google Scholar
• Walraven CJ, North MS, Marr-Lyon L, et al. Site of infection rather than vancomycin MIC predicts vancomycin treatment failure in methicillin-resistant Staphylococcus aureus bacteraemia. J Antimicrob Chemother 2011;66:2386-92
   PubMed Web of Science ®Google Scholar
• Stephens JM, Gao X, Patel DA, et al. Economic burden of inpatient and outpatient antibiotic treatment for methicillin-resistant Staphylococcus aureus complicated skin and soft-tissue infections: a comparison of linezolid, vancomycin, and daptomycin. Clinicoecon Outcomes Res 2013;5:447-57
   PubMedGoogle Scholar
• Bounthavong M, Zargarzadeh A, Hsu DI, Vanness DJ. Cost-effectiveness analysis of linezolid, daptomycin, and vancomycin in methicillin-resistant Staphylococcus aureus: complicated skin and skin structure infection using Bayesian methods for evidence synthesis. Value Health 2011;14:631-9
   PubMed Web of Science ®Google Scholar
• Bhavnani SM, Prakhya A, Hammel JP, Ambrose PG. Cost-Effectiveness of daptomycin versus vancomycin and gentamicin for patients with methicillin-resistant Staphylococcus aureus bacteremia and/or endocarditis. Clin Infect Dis 2009;49:691-8
   PubMed Web of Science ®Google Scholar
• Pea F, Viale P. The antimicrobial therapy puzzle: could pharmacokinetic-pharmacodynamic relationships be helpful in addressing the issue of appropriate pneumonia treatment in critically ill patients? Clin Infect Dis 2006;42:1764-71
   PubMed Web of Science ®Google Scholar
• Dellit TH, Owens RC, McGowan JEJr, et al.Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America guidelines for developing an institutional program to enhance antimicrobial stewardship. Clin Infect Dis 2007;44:159-77
   PubMed Web of Science ®Google Scholar
• Mortin LI, Li T, Van Praagh AD, et al. Rapid bactericidal activity of daptomycin against methicillin-resistant and methicillin-susceptible Staphylococcus aureus peritonitis in mice as measured with bioluminescent bacteria. Antimicrob Agents Chemother 2007;51:1787-94
   PubMed Web of Science ®Google Scholar
• Marco F, de la Maria CG, Armero Y, et al. Daptomycin is effective in treatment of experimental endocarditis due to methicillin-resistant and glycopeptide-intermediate Staphylococcus aureus. Antimicrob Agents Chemother 2008;52:2538-43
   PubMed Web of Science ®Google Scholar
• Moore CL, Osaki-Kiyan P, Haque NZ, et al. Daptomycin versus vancomycin for bloodstream infections due to methicillin-resistant Staphylococcus aureus with a high vancomycin minimum inhibitory concentration: a case-control study. Clin Infect Dis 2012;54:51-8
   PubMed Web of Science ®Google Scholar
• Murray KP, Zhao JJ, Davis SL, et al. Early use of daptomycin versus vancomycin for methicillin-resistant Staphylococcus aureus bacteremia with vancomycin minimum inhibitory concentration >1 mg/L: a matched cohort study. Clin Infect Dis 2013;56:1562-9
   PubMed Web of Science ®Google Scholar
• Cheng CW, Hsu PC, Yang CC, et al. Influence of early daptomycin therapy on treatment outcome of meticillin-resistant Staphylococcus aureus bacteraemia with high vancomycin minimum inhibitory concentrations. Int J Antimicrob Agents 2013;41:293-4
   PubMed Web of Science ®Google Scholar
• Dilworth TJ, Ibrahim O, Hall P, et al. Beta-Lactams enhance vancomycin activity against methicillin-resistant Staphylococcus aureus bacteremia compared to vancomycin alone. Antimicrob Agents Chemother 2014;58:102-9
   PubMed Web of Science ®Google Scholar
• Hagihara M, Wiskirchen DE, Kuti JL, Nicolau DP. In vitro pharmacodynamics of vancomycin and cefazolin alone and in combination against methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 2012;56:202-7
   PubMed Web of Science ®Google Scholar
• Leonard SN. Synergy between vancomycin and nafcillin against Staphylococcus aureus in an in vitro pharmacokinetic/pharmacodynamic model. Plos One 2012;7:e42103
   PubMed Web of Science ®Google Scholar
• Palmer SM, Rybak MJ. An evaluation of the bactericidal activity of ampicillin/sulbactam, piperacillin/tazobactam, imipenem or nafcillin alone and in combination with vancomycin against methicillin-resistant Staphylococcus aureus (MRSA) in time-kill curves with infected fibrin clots. J Antimicrob Chemother 1997;39:515-18
   PubMed Web of Science ®Google Scholar
• Holland TL, Arnold C, Fowler VGJr, et al.Clinical management of Staphylococcus aureus bacteremia: a review. JAMA 2014;312:1330-41
   PubMed Web of Science ®Google Scholar
• McConeghy KW, Bleasdale SC, Rodvold KA. The empirical combination of vancomycin and a beta-lactam for Staphylococcal bacteremia. Clin Infect Dis 2013;57:1760-5
   PubMed Web of Science ®Google Scholar
• Liu C, Bayer A, Cosgrove SE, et al. Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children. Clin Infect Dis 2011;52:e18-55
   PubMed Web of Science ®Google Scholar
• Fowler VGJr, Boucher HW, Corey GR, et al. Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus. N Engl J Med 2006;355:653-65
   PubMed Web of Science ®Google Scholar
• Sharma M, Riederer K, Chase P, Khatib R. High rate of decreasing daptomycin susceptibility during the treatment of persistent Staphylococcus aureus bacteremia. Eur J Clin Microbiol Infect Dis 2008;27:433-7
   PubMed Web of Science ®Google Scholar
• LaPlante KL, Rybak MJ. Impact of high-inoculum Staphylococcus aureus on the activities of nafcillin, vancomycin, linezolid, and daptomycin, alone and in combination with gentamicin, in an in vitro pharmacodynamic model. Antimicrob Agents Chemother 2004;48:4665-72
   PubMed Web of Science ®Google Scholar
• Michiels MJ, Bergeron MG. Differential increased survival of staphylococci and limited ultrastructural changes in the core of infected fibrin clots after daptomycin administration. Antimicrob Agents Chemother 1996;40:203-11
   PubMed Web of Science ®Google Scholar
• Skiest DJ. Treatment failure resulting from resistance of Staphylococcus aureus to daptomycin. J Clin Microbiol 2006;44:655-6
   PubMed Web of Science ®Google Scholar
• Tenover FC, Sinner SW, Segal RE, et al. Characterisation of a Staphylococcus aureus strain with progressive loss of susceptibility to vancomycin and daptomycin during therapy. Int J Antimicrob Agents 2009;33:564-8
   PubMed Web of Science ®Google Scholar
• Bassetti M, Villa G, Ansaldi F, et al. Risk factors associated with the onset of daptomycin non-susceptibility in Staphylococcus aureus infections in critically ill patients. Intensive Care Med 2015;41:366-8
   PubMed Web of Science ®Google Scholar
• Gasch O, Camoez M, Dominguez MA, et al. Emergence of resistance to daptomycin in a cohort of patients with methicillin-resistant Staphylococcus aureus persistent bacteraemia treated with daptomycin. J Antimicrob Chemother 2014;69:568-71
   PubMed Web of Science ®Google Scholar
• Gould IM, Miro JM, Rybak MJ. Daptomycin: the role of high-dose and combination therapy for Gram-positive infections. Int J Antimicrob Agents 2013;42:202-10
   PubMed Web of Science ®Google Scholar
• Cha R, Rybak MJ. Daptomycin against multiple drug-resistant staphylococcus and enterococcus isolates in an in vitro pharmacodynamic model with simulated endocardial vegetations. Diagn Microbiol Infect Dis 2003;47:539-46
   PubMed Web of Science ®Google Scholar
• Leonard SN, Rybak MJ. Evaluation of vancomycin and daptomycin against methicillin-resistant Staphylococcus aureus and heterogeneously vancomycin-intermediate S. aureus in an in vitro pharmacokinetic/pharmacodynamic model with simulated endocardial vegetations. J Antimicrob Chemother 2009;63:155-60
   PubMed Web of Science ®Google Scholar
• Garrigos C, Murillo O, Euba G, et al. Efficacy of usual and high doses of daptomycin in combination with rifampin versus alternative therapies in experimental foreign-body infection by methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 2010;54:5251-6
   PubMed Web of Science ®Google Scholar
• Murillo O, Garrigos C, Pachon ME, et al. Efficacy of high doses of daptomycin versus alternative therapies against experimental foreign-body infection by methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 2009;53:4252-7
   PubMed Web of Science ®Google Scholar
• Blot SI, Pea F, Lipman J. The effect of pathophysiology on pharmacokinetics in the critically ill patient–concepts appraised by the example of antimicrobial agents. Adv Drug Deliv Rev 2014;77:3-11
   PubMed Web of Science ®Google Scholar
• Falcone M, Russo A, Venditti M, et al. Considerations for higher doses of daptomycin in critically ill patients with methicillin-resistant Staphylococcus aureus bacteremia. Clin Infect Dis 2013;57:1568-76
   PubMed Web of Science ®Google Scholar
• Roberts JA, Pea F, Lipman J. The clinical relevance of plasma protein binding changes. Clin Pharmacokinet 2013;52:1-8
   PubMed Web of Science ®Google Scholar
• Pea F, Crapis M, Cojutti P, Bassetti M. Daptomycin underexposure in a young intravenous drug user who was affected by life-threatening Staphylococcus aureus-complicated skin and soft tissue infection associated with bacteraemia. Infection 2014;42:207-10
   PubMed Web of Science ®Google Scholar
• Pea F. Plasma pharmacokinetics of antimicrobial agents in critically ill patients. Curr Clin Pharmacol 2013;8:5-12
   PubMedGoogle Scholar
• Bhavnani SM, Rubino CM, Ambrose PG, Drusano GL. Daptomycin exposure and the probability of elevations in the creatine phosphokinase level: data from a randomized trial of patients with bacteremia and endocarditis. Clin Infect Dis 2010;50:1568-74
   PubMed Web of Science ®Google Scholar
• Rose WE, Leonard SN, Rybak MJ. Evaluation of daptomycin pharmacodynamics and resistance at various dosage regimens against Staphylococcus aureus isolates with reduced susceptibilities to daptomycin in an in vitro pharmacodynamic model with simulated endocardial vegetations. Antimicrob Agents Chemother 2008;52:3061-7
   PubMed Web of Science ®Google Scholar
• Saleh-Mghir A, Muller-Serieys C, Dinh A, et al. Adjunctive rifampin is crucial to optimizing daptomycin efficacy against rabbit prosthetic joint infection due to methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 2011;55:4589-93
   PubMed Web of Science ®Google Scholar
• Cirioni O, Mocchegiani F, Ghiselli R, et al. Daptomycin and rifampin alone and in combination prevent vascular graft biofilm formation and emergence of antibiotic resistance in a subcutaneous rat pouch model of staphylococcal infection. Eur J Vasc Endovasc Surg 2010;40:817-22
   PubMed Web of Science ®Google Scholar
• John AK, Baldoni D, Haschke M, et al. Efficacy of daptomycin in implant-associated infection due to methicillin-resistant Staphylococcus aureus: importance of combination with rifampin. Antimicrob Agents Chemother 2009;53:2719-24
   PubMed Web of Science ®Google Scholar
• Rose WE, Berti AD, Hatch JB, Maki DG. Relationship of in vitro synergy and treatment outcome with daptomycin plus rifampin in patients with invasive methicillin-resistant Staphylococcus aureus infections. Antimicrob Agents Chemother 2013;57:3450-2
   PubMed Web of Science ®Google Scholar
• Ahmad NM, Rojtman AD. Successful treatment of daptomycin-nonsusceptible methicillin-resistant Staphylococcus aureus bacteremia with the addition of rifampin to daptomycin. Ann Pharmacother 2010;44:918-21
   PubMed Web of Science ®Google Scholar
• Moise PA, Amodio-Groton M, Rashid M, et al. Multicenter evaluation of the clinical outcomes of daptomycin with and without concomitant beta-lactams in patients with Staphylococcus aureus bacteremia and mild to moderate renal impairment. Antimicrob Agents Chemother 2013;57:1192-200
   PubMed Web of Science ®Google Scholar
• Yang SJ, Xiong YQ, Boyle-Vavra S, et al. Daptomycin-oxacillin combinations in treatment of experimental endocarditis caused by daptomycin-nonsusceptible strains of methicillin-resistant Staphylococcus aureus with evolving oxacillin susceptibility (the “seesaw effect”). Antimicrob Agents Chemother 2010;54:3161-9
   PubMed Web of Science ®Google Scholar
• Rand KH, Houck HJ. Synergy of daptomycin with oxacillin and other beta-lactams against methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 2004;48:2871-5
   PubMed Web of Science ®Google Scholar
• Garrigos C, Murillo O, Lora-Tamayo J, et al. Efficacy of daptomycin-cloxacillin combination in experimental foreign-body infection due to methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 2012;56:3806-11
   PubMed Web of Science ®Google Scholar
• Shaw E, Miro JM, Puig-Asensio M, et al. Daptomycin plus fosfomycin versus daptomycin monotherapy in treating MRSA: protocol of a multicentre, randomised, Phase III trial. BMJ Open 2015;5:e006723
   PubMed Web of Science ®Google Scholar
• Weston A, Boucher HW. Daptomycin for methicillin-resistant Staphylococcus aureus bloodstream infection and elevated vancomycin minimum inhibitory concentrations: has the time come? Clin Infect Dis 2012;54:59-61
   PubMed Web of Science ®Google Scholar
• Wunderink RG, Niederman MS, Kollef MH, et al. Linezolid in methicillin-resistant Staphylococcus aureus nosocomial pneumonia: a randomized, controlled study. Clin Infect Dis 2012;54:621-9
   PubMed Web of Science ®Google Scholar
• Segarra-Newnham M, Church TJ. Pharmacotherapy for methicillin-resistant Staphylococcus aureus nosocomial pneumonia. Ann Pharmacother 2012;46:1678-87
   PubMed Web of Science ®Google Scholar
• Alaniz C, Pogue JM. Vancomycin versus linezolid in the treatment of methicillin-resistant Staphylococcus aureus nosocomial pneumonia: implications of the ZEPHyR trial. Ann Pharmacother 2012;46:1432-5
   PubMed Web of Science ®Google Scholar
• Masuta K, Oba Y, Iwata K. Linezolid versus vancomycin for methicillin-resistant Staphylococcus aureus nosocomial pneumonia: controversy continues. Clin Infect Dis 2012;55:161
   PubMed Web of Science ®Google Scholar
• An MM, Shen H, Zhang JD, et al. Linezolid versus vancomycin for meticillin-resistant Staphylococcus aureus infection: a meta-analysis of randomised controlled trials. Int J Antimicrob Agents 2013;41:426-33
   PubMed Web of Science ®Google Scholar
• Kalil AC, Klompas M, Haynatzki G, Rupp ME. Treatment of hospital-acquired pneumonia with linezolid or vancomycin: a systematic review and meta-analysis. BMJ Open 2013;3:e003912
   PubMed Web of Science ®Google Scholar
• Jiang H, Tang RN, Wang J. Linezolid versus vancomycin or teicoplanin for nosocomial pneumonia: meta-analysis of randomised controlled trials. Eur J Clin Microbiol Infect Dis 2013;32:1121-8
   PubMed Web of Science ®Google Scholar
• Martinez-Olondris P, Rigol M, Soy D, et al. Efficacy of linezolid compared to vancomycin in an experimental model of pneumonia induced by methicillin-resistant Staphylococcus aureus in ventilated pigs. Crit Care Med 2012;40:162-8
   PubMed Web of Science ®Google Scholar
• Stein GE, Wells EM. The importance of tissue penetration in achieving successful antimicrobial treatment of nosocomial pneumonia and complicated skin and soft-tissue infections caused by methicillin-resistant Staphylococcus aureus: vancomycin and linezolid. Curr Med Res Opin 2010;26:571-88
   PubMed Web of Science ®Google Scholar
• Jacqueline C, Broquet A, Roquilly A, et al. Linezolid dampens neutrophil-mediated inflammation in methicillin-resistant staphylococcus aureus-induced pneumonia and protects the lung of associated damages. J Infect Dis 2014;210:814-23
   PubMed Web of Science ®Google Scholar
• Chung DR, Huh K. Novel pandemic influenza A (H1N1) and community-associated methicillin-resistant Staphylococcus aureus pneumonia. Expert Rev Anti Infect Ther 2015;13:197-207
   PubMed Web of Science ®Google Scholar
• Bhan U, Podsiad AB, Kovach MA, et al. Linezolid has unique immunomodulatory effects in post-influenza community acquired MRSA pneumonia. Plos One 2015;10:e0114574
   PubMedGoogle Scholar
• Almansa R, Wain J, Tamayo E, et al. Immunological monitoring to prevent and treat sepsis. Crit Care 2013;17:109
   PubMedGoogle Scholar
• Lee YL, Chen W, Chen LY, et al. Systemic and bronchoalveolar cytokines as predictors of in-hospital mortality in severe community-acquired pneumonia. J Crit Care 2010;25:176 e177-13
   Google Scholar
• Peyrani P, Wiemken TL, Kelley R, et al. Higher clinical success in patients with ventilator-associated pneumonia due to methicillin-resistant Staphylococcus aureus treated with linezolid compared with vancomycin: results from the IMPACT-HAP study. Crit Care 2014;18:R118
   PubMed Web of Science ®Google Scholar
• Mendes RE, Deshpande LM, Jones RN. Linezolid update: stable in vitro activity following more than a decade of clinical use and summary of associated resistance mechanisms. Drug Resist Updat 2014;17:1-12
   PubMed Web of Science ®Google Scholar
• Pea F, Viale P. Could de-escalation of antibiotic therapy be feasible even for documented methicillin-resistant Staphylococcus aureus ventilator-associated pneumonia? J Trauma 2009;67:893-4
   PubMed Web of Science ®Google Scholar
• McDanel JS, Perencevich EN, Diekema DJ, et al. Comparative effectiveness of beta-lactams versus vancomycin for treatment of methicillin-susceptible staphylococcus aureus bloodstream infections among 122 hospitals. Clin Infect Dis 2015. [Epub ahead of print]
   PubMed Web of Science ®Google Scholar